Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait
Primary Purpose
Transcranial Magnetic Stimulation, Freezing of Gait
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Transcranial Magnetic Stimulation
Sponsored by

About this trial
This is an interventional treatment trial for Transcranial Magnetic Stimulation focused on measuring Transcranial Magnetic Stimulation, Freezing of gait
Eligibility Criteria
Inclusion Criteria:
- diagnosis of FOG with expertise in movement disorders.
- the score of item 3 of the FOG questionnaire ≥1.
- ongoing treatment with a stable dose of any medication for 2 months.
- 40 years of age or older.
Exclusion Criteria:
- a history of addiction, psychiatric disorders, or neurological diseases other than PD.
- focal brain lesions on T1-/T2-weighted fluid-attenuated inversion recovery images.
- anti-PD medication adjustments during rTMS treatment.
- history of substance abuse within the past 6 months.
- nonremovable metal objects in or around the head.
- previously received rTMS treatment.
- prior history of seizure or history in first-degree relatives.
Sites / Locations
- Cognitive Neuropsychology Lab Anhui Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
TBS Group
Arm Description
Participants will receive active transcranial magnetic stimulation (TMS) daily for 1 week
Outcomes
Primary Outcome Measures
The Standing-Start 180° Turn Test (SS-180)
The participants walk for a distance of five meters from a sitting position and come back to the chair after turning 180° around a traffic cone in a 0.7 m × 0.7 m target box.The time and number of steps during the 180° turn (SS180) are measured.
Secondary Outcome Measures
The timed up and go test (TUG)
The participants walk for a distance of five meters from a sitting position and come back to the chair after turning 180° around a traffic cone in a 0.7 m × 0.7 m target box .The time and number of steps during the whole course are measured.
The Freezing of Gait Questionnaire (FOGQ)
This is an very common clinical motor estimating scale for evaluating FOG symptoms with 6 items and 24' in total. Higher scores indicate worse symptoms.
Unified Parkinson's Disease Rating Scale III (UPDRSIII)
This is an very common clinical motor estimating scale, 14 items and 108' in total. Higher scores indicate worse symptoms.
Non-motor symptoms questionnaire
This is a very common clinical scale with nine domains (30 items). Each item was scored on "severity" range from 1 to 3 and "frequency" range from 1 to 4. Higher scores indicate worse symptoms.
HAMD (Hamilton Depression Scale)
This scale was compiled by Hamilton in 1960, is the most common clinical to assess Depression Scale. In this study, 17 versions were selected, and there were 17 questions. The subjects were assessed for their depression in the past week. Each question scored between 0 and 4 points.Higher scores indicate more depressive symptoms.
HAMA (Hamilton Anxiety Scale)
This scale was compiled by Hamilton in 1959.It was one of the most commonly used scales in psychiatric clinic, including 14 items. It is often used in clinical diagnosis and degree classification of anxiety disorder. The subjects were assessed for their anxiety in the past week. Each question scored between 0 and 4 points. The higher the score, the more symptoms of anxiety.
Pittsburgh sleep quality index (PSQI)
This scale was developed by Dr. Buysse et al., a psychiatrist at the University of Pittsburgh in 1989. The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general.Each question scored between 0 and 3 points.The higher the score, the worse sleep quality.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05192759
Brief Title
Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait
Official Title
Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 22, 2021 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Anhui Medical University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To investigate the treatment effect of Theta-burst Transcranial Magnetic Stimulation (TBS) on patients with freezing of gait (FOG) and the underlying neural mechanism.
Detailed Description
This was a open-label clinical trial to assess the efficacy and underlying neural mechanism of TBS among patients with FOG. Forty patients with FOG were treated with TBS for 1 week.
Before the TBS treatment, the Freezing of Gait Questionnaire, the Timed up and go test, the Standing Start 180° Turning Test, the Unified Parkinson's Disease Rating Scale, and the Non-motor Symptom Scale, the Pittsburgh sleep quality index were obtained by a trained investigator to assess baseline severity. The patients had receiving a battery measure of neuropsychological tests(mini-mental state examination, Montreal cognitive assessment, digital span test, verbal fluency test, Hamilton depression/anxiety scale) and magnetic resonance imaging (MRI) scan in multimodalities, and electroencephalography (EEG) record.
In the second day after the last treatment, all the tests, MRI and EEG were reassessed. Patients were instructed to focus their answers on the past 1 week.
The clinical symptom and cognition of participants were followed in one month and two month after the last treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transcranial Magnetic Stimulation, Freezing of Gait
Keywords
Transcranial Magnetic Stimulation, Freezing of gait
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TBS Group
Arm Type
Experimental
Arm Description
Participants will receive active transcranial magnetic stimulation (TMS) daily for 1 week
Intervention Type
Device
Intervention Name(s)
Transcranial Magnetic Stimulation
Intervention Description
The stimulations were performed by MagStim Rapid2.
Primary Outcome Measure Information:
Title
The Standing-Start 180° Turn Test (SS-180)
Description
The participants walk for a distance of five meters from a sitting position and come back to the chair after turning 180° around a traffic cone in a 0.7 m × 0.7 m target box.The time and number of steps during the 180° turn (SS180) are measured.
Time Frame
changes from baseline to 1-week post-treatment
Secondary Outcome Measure Information:
Title
The timed up and go test (TUG)
Description
The participants walk for a distance of five meters from a sitting position and come back to the chair after turning 180° around a traffic cone in a 0.7 m × 0.7 m target box .The time and number of steps during the whole course are measured.
Time Frame
changes from baseline to 1-week post-treatment
Title
The Freezing of Gait Questionnaire (FOGQ)
Description
This is an very common clinical motor estimating scale for evaluating FOG symptoms with 6 items and 24' in total. Higher scores indicate worse symptoms.
Time Frame
changes from baseline to 1-week post-treatment
Title
Unified Parkinson's Disease Rating Scale III (UPDRSIII)
Description
This is an very common clinical motor estimating scale, 14 items and 108' in total. Higher scores indicate worse symptoms.
Time Frame
changes from baseline to 1-week post-treatment
Title
Non-motor symptoms questionnaire
Description
This is a very common clinical scale with nine domains (30 items). Each item was scored on "severity" range from 1 to 3 and "frequency" range from 1 to 4. Higher scores indicate worse symptoms.
Time Frame
changes from baseline to 1-week post-treatment
Title
HAMD (Hamilton Depression Scale)
Description
This scale was compiled by Hamilton in 1960, is the most common clinical to assess Depression Scale. In this study, 17 versions were selected, and there were 17 questions. The subjects were assessed for their depression in the past week. Each question scored between 0 and 4 points.Higher scores indicate more depressive symptoms.
Time Frame
changes from baseline to 1-week post-treatment
Title
HAMA (Hamilton Anxiety Scale)
Description
This scale was compiled by Hamilton in 1959.It was one of the most commonly used scales in psychiatric clinic, including 14 items. It is often used in clinical diagnosis and degree classification of anxiety disorder. The subjects were assessed for their anxiety in the past week. Each question scored between 0 and 4 points. The higher the score, the more symptoms of anxiety.
Time Frame
changes from baseline to 1-week post-treatment
Title
Pittsburgh sleep quality index (PSQI)
Description
This scale was developed by Dr. Buysse et al., a psychiatrist at the University of Pittsburgh in 1989. The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general.Each question scored between 0 and 3 points.The higher the score, the worse sleep quality.
Time Frame
changes from baseline to 1-week post-treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diagnosis of FOG with expertise in movement disorders.
the score of item 3 of the FOG questionnaire ≥1.
ongoing treatment with a stable dose of any medication for 2 months.
40 years of age or older.
Exclusion Criteria:
a history of addiction, psychiatric disorders, or neurological diseases other than PD.
focal brain lesions on T1-/T2-weighted fluid-attenuated inversion recovery images.
anti-PD medication adjustments during rTMS treatment.
history of substance abuse within the past 6 months.
nonremovable metal objects in or around the head.
previously received rTMS treatment.
prior history of seizure or history in first-degree relatives.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gong-Jun JI, Ph.D.
Phone
+8655162923704
Email
jigongjun@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jinmei Sun, M.S.
Phone
+8615856381782
Email
sunjinmei0628@163.com
Facility Information:
Facility Name
Cognitive Neuropsychology Lab Anhui Medical University
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gong-Jun JI, Ph.D.
Phone
+8655162923704
Email
jigongjun@163.com
First Name & Middle Initial & Last Name & Degree
Jinmei Sun, M.S.
Phone
+8615856381782
Email
sunjinmei0628@163.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait
We'll reach out to this number within 24 hrs